|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Dyax_Corp.
gptkb:Alder_BioPharmaceuticals
gptkb:Baxalta_Incorporated
gptkb:NPS_Pharmaceuticals
gptkb:Talecris_Biotherapeutics
|
|
gptkbp:employees
|
over 5,000
|
|
gptkbp:founded
|
1986
|
|
gptkbp:founder
|
gptkb:Helen_O'Neill
|
|
gptkbp:headquarters
|
gptkb:Dublin,_Ireland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Shire Pharmaceuticals Ireland Limited
|
|
gptkbp:industry
|
Biotechnology
|
|
gptkbp:location
|
gptkb:Ireland
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
Sanofi
|
|
gptkbp:products
|
gptkb:Fosrenol
Adderall
Cerezyme
Intuniv
Vyvanse
|
|
gptkbp:researchFocus
|
gptkb:Gaucher_disease
gptkb:Hunter_syndrome
gptkb:Fabry_disease
gptkb:Hemophilia
Multiple sclerosis
Oncology
Depression
Crohn's disease
Cystic fibrosis
Schizophrenia
Ulcerative colitis
Anxiety disorders
Neurodegenerative diseases
Attention Deficit Hyperactivity Disorder (ADHD)
Chronic pain
Autism spectrum disorders
Rare genetic disorders
|
|
gptkbp:revenue
|
$15 billion (2017)
|
|
gptkbp:specializesIn
|
rare diseases
|
|
gptkbp:subsidiary
|
gptkb:Shire_Pharmaceuticals_Inc.
gptkb:Shire_US_Holdings
gptkb:Shire_International_GmbH
gptkb:Shire_Development_LLC
|
|
gptkbp:type
|
Public company
|
|
gptkbp:website
|
www.shire.com
|